

Table 1 - Cascade data for 32 Full cascades and 37 Partial cascades

Country (year)	% of all PLHIV diagnosed	% of those Diagnosed receiving ART	% of those on ART achieving viral suppression	Final % of all PLHIV receiving ART	Final % of PLHIV achieving viral suppression	Viral suppression cut-of used	Total epidemic size	UNAIDS total estimated epidemic size at year of cascade	Source (Cross sectional or Longitudinal)
UNAIDS Targets^{1,11}	90%	90%	90%	81%	73%	<1,000	-	-	UNAIDS
Global^{1,11} (2014)	54%	75%	67%	40%	27%	<1,000	36.9 million	36.9 million	UNAIDS
32 Full Cascades									
Switzerland¹ (2012)	81%	88%	96%	71%	68%	<200	15,200	19,000	Combined
United Kingdom² (2013)	76%	90%	90%	68%	61%	<200	107,800	130,000	Cross Sectional
Rwanda³ (2014)	86%	79%	86%	68%	58%	<40	209,180	210,000	Cross Sectional
Australia⁴	86%	76%	93%	66%	62%	<400	26,764	28,000	Cross Sectional

(2013) Netherlands⁵	87%	73%	91%	64%	58%	<200	25,000	21,250	Cross Sectional
(2013) Thailand⁶	80%	76%	71%	61%	43%	<50	445,503	450,000	Cross Sectional
(2014) France⁷	81%	74%	86%	60%	52%	<50	149,000	NA	Cross Sectional
(2010) Zimbabwe^{8,9}	66%	77%	70%	51%	36%	<500*	1,328,535	1,550,250	Combination
(2011-13) Austria¹⁰	80%	62%	91%	50%	45%	NA	7,983	18,000	Cross Sectional
(2014) Brazil¹¹	80%	60%	72%	48%	35%	<50	734,000	730,000	Cross Sectional
(2013) Argentina⁸	71%	66%	66%	47%	31%	<50	110,000	117,907	Cross Sectional
(2012) Cuba¹²	75%	55%	73%	41%	30%	NA	19,626	13,364	Cross Sectional
(2012) Mexico¹³	67%	60%	62%	40%	25%	NA	204,000	194,501	Cross Sectional

(2012)									
Venezuela¹³	54%	70%	31%	38%	12%	NA	110,000	110,000	Cross Sectional
(2012)									
USA¹⁴	86%	43%	81%	37%	30%	<200	1,200,000	920,000 - 1,800,000	Cross Sectional
(2012)									
Peru¹³	53%	67%	51%	36%	18%	NA	76,000	65,000	Cross Sectional
(2012)									
Mauritius¹⁵	66%	53%	62%	35%	22%	<1,000	9,200	8,300	Cross Sectional
(2014)									
Kenya¹⁶	51%	67%	79%	34%	27%	<1,000	1,356,540	1,366,920	Longitudinal Survey
(2012)									
(15+ years)									
Georgia¹⁷	56%	60%	82%	34%	28%	<400	6,600	6,600	Cross Sectional
(2014)									
Vietnam¹⁸	85%	37%	78%	31%	24%	NA	254,950	250,000	Cross Sectional
(2013)									
Estonia¹⁹	87%	33%	66%	29%	19%	<200	9,279	8,600	Cross Sectional
(2013)									
Paraguay⁸	74%	38%	70%	28%	18%	NA	16,825	17,000	Cross Sectional

Russia²³ (2013)	49%	23%	81%	12%	9%	<1,000	1,363,330	850,000 - 1,300,000	Cross Sectional
Country (year)	% of all PLHIV diagnosed	% of those Diagnosed receiving ART	% of those on ART achieving viral suppression	Final % of all PLHIV receiving ART	Final % of PLHIV achieving viral suppression	Viral suppression cut-of used	Reported Total epidemic size	UNAIDS estimated total epidemic Size	Source (Cross sectional or Longitudinal)
37 Partial Cascades									
Botswana^{8,9} (2014)	NA	NA	79%	63%	50%	<400*	392,321	392,427	Combination
Zambia^{8,9} (2014)	NA	NA	73%	56%	41%	<400*	1,200,000	1,150,370	Combination
Uganda^{8,9} (2014)	NA	NA	67%	51%	34%	<1,000	1,500,000	1,486,640	Combination
Malawi⁸ (2014)	NA	NA	84%	49%	42%	NA	1,100,000	1,063,910	Combination
Guyana⁸	86%	57%	NA	49%	NA	NA	7,200	7,500	Cross Sectional

Panama⁸ (2012)	70%	48%	NA	33%	NA	NA	17,000	15,000	Cross Sectional
Morocco⁸ (2014)	35%	75%	NA	N6%	NA	NA	28,829	28,740	Cross Sectional
Cote d'Ivoire^{8,9} (2012)	NA	NA	55%	24%	13%	<300*	450,000	462,301	Combination
Egypt 15+⁸ (2014)	64%	37%	NA	24%	NA	NA	7,200	8,810	Cross Sectional
Guatemala¹³ (2012)	39%	63%	NA	24%	NA	NA	58,000	NA	Cross Sectional
Fiji⁸ (2013)	65%	32%	NA	21%	NA	NA	1,000	660	Cross Sectional
Philippines⁸ (2013)	59%	34%	NA	20%	NA	NA	28,072	34,000	Cross Sectional
Nigeria^{8,9} (2013)	NA	NA	72%	20%	14%	<400*	3,229,757	3,400,000	Combination
Cameroon^{8,9} (2013)	NA	NA	65%	20%	14%	<500*	600,000	600,000	Combination

Kyrgyzstan²⁴ (2014)	70%	27%	NA	19%	NA	NA	8,021	9,259	Cross Sectional
Moldova⁸ (2014)	39%	46%	NA	18%	NA	NA	17,541	NA	Cross Sectional
Montenegro⁸ (2014)	29%	61%	NA	18%	NA	NA	463	<1,000	Cross Sectional
Ecuador¹³ (2012)	36%	49%	NA	17%	NA	NA	52,000	32,678	Cross Sectional
Bhutan⁸ (2014)	40%	41%	NA	17%	NA	NA	1,000	NA	Cross Sectional
Bolivia¹³ (2012)	39%	37%	NA	14%	NA	NA	16,000	16,749	Cross Sectional
Tunisia⁸ (2013)	33%	42%	NA	14%	NA	NA	3,991	2,688	Cross Sectional
Indonesia⁶⁶ (2014)	32%	23%	NA	7%	NA	NA	590,000	660,272	Cross Sectional
Iran⁸ (2014)	30%	24%	NA	7%	NA	NA	75,000	74,370	Cross Sectional

Yemen⁸ (2013)	11%	24%	NA	3%	NA	NA	35,000	7,200	Cross Sectional
Afghanistan⁸ (2012)	31%	11%	NA	3%	NA	NA	4,948	5,627	Cross Sectional
Belgium²⁵ (2010)	NA	72%	95%	NA	NA	<500	NA	NA	Longitudinal
Denmark²⁶ (2010)	NA	73%	96%	NA	NA	<500	NA	5,000	Longitudinal
Dominica⁸ (2014)	NA	68%	54%	NA	NA	NA	NA	NA	Cross Sectional

The numbers in **bold** identify the main 'breakpoint' – the greatest point of attrition in each countries cascade.

* Countries viral suppression percentage was estimated using a systematic review on viral suppression rates for sub-Saharan African Countries.⁹

References

50. Kohler P, Schmidt AJ, Cavassini M, et al. Swiss HIV Cohort Study. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. *AIDS* 2015;29: 2509–15.
51. Gisinger M, Kitchen M, Leierer G, et al. HIV/AIDS in Austria 26 the Report of the Austrian HIV Cohort Study. Report number: 26; 2014.
52. Alonso-González M. Antiretroviral treatment in the spotlight: a public health analysis in Latin America and the Caribbean. Washington: Pan American Health Organization (PAHO), 2012:52.
53. Piñeirúa A, Sierra-Madero J, Cahn P, et al. The HIV care continuum in Latin America: challenges and opportunities. *Lancet Infect Dis* 2015;15:833–9.
54. Amita Pathak. HIV treatment cascade as at December 2014 Republic of Mauritius. Mauritius July report International AIDS Society. 2015; Achieving 90-90-90 by 2020.
55. Kenya A. Indicator Survey 2012. Preliminary Report. Nairobi: National AIDS and STI Control Programme, Ministry of Health Kenya, 2013.
56. Chkhartishvili N, Sharavdze L, Chokoshvili O, et al. The cascade of care in the Eastern European country of Georgia. *HIV Med* 2015;16:62–6.
57. Kato M, Long NH, Duong BD, et al. Enhancing the Benefits of Antiretroviral Therapy in Vietnam: Towards Ending AIDS. *Curr HIV/ AIDS Rep* 2014;11:487–95.
58. Raben D, Jakobsen SF, Nakagawa F, et al. HIV/AIDS treatment and care in Estonia. Evaluation report. WHO Collaborating Centre for HIV and Viral Hepatitis; June 2014.
59. Kazatchkine M. Treatment cascade for Ukraine. Drug use, HIV, HCV and TB: major interlinked challenges in Eastern Europe and Central Asia. United Nations Switzerland Oral Presentation, HIV Drug Therapy, November 2014 Glasgow, Slide 12. Nov 3rd 2014(Special Envoy for HIV/AIDS in Eastern Europe and Central Asia, Geneva.
60. Raben DJK. HIV programme review in Belarus. CHIP and WHO. Evaluation Report (National health programme), 2014.
61. Lo YR, Kato M, Phanuphak N, et al. Challenges and potential barriers to the uptake of antiretroviral-based prevention in Asia and the Pacific region. *Sex Health* 2014;11:126–36.
62. Mansfeld M, Ristol M, Likatavicius G. HIV treatment cascade for Kyrgyzstan. HIV Programme Review in Kyrgyzstan Evaluation report. December 2012; WHO Collaborating Centre for HIV and Viral Hepatitis (Figure 1, page 11).
63. Van Beckhoven D, Lacor P, Moutschen M, et al. Factors associated with the continuum of care of HIV-infected patients in Belgium. *J Int AIDS Soc* 2014;17(Suppl 3):19534.
64. Helleberg M, Häggblom A, Sönnberg A, et al. HIV Care in the Swedish-Danish HIV Cohort 1995–2010. Closing the Gaps. e72257. *PLoS ONE* 2013;8:e72257.
65. Takuca S, Brown A, Macleod W, et al. Disparities in engagement within care in South Africa. Seattle, Washington February 23–36th, 2015, The Annual Conference on Retroviruses and Opportunistic Infections (CROI); Abstract 154.
66. Siti Natia Wiweko, et al. Introduction of the strategic use of ARVs for treatment and prevention in Indonesia: from policy to implementation. Data from MOH 2014. International AIDS Conference; Australia, 2014.